These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12696108)

  • 21. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA.
    Vlotides G; Sörensen AS; Kopp F; Zitzmann K; Cengic N; Brand S; Zachoval R; Auernhammer CJ
    Biochem Biophys Res Commun; 2004 Jul; 320(3):1007-14. PubMed ID: 15240148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Garcia A; Moore PA; Yu R; Subramanian GM
    Antivir Ther; 2006; 11(7):901-8. PubMed ID: 17302252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-Stimulated Genes-Mediators of the Innate Immune Response during Canine Distemper Virus Infection.
    Klotz D; Gerhauser I
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30939763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment.
    Chen L; Sun J; Meng L; Heathcote J; Edwards AM; McGilvray ID
    J Gen Virol; 2010 Feb; 91(Pt 2):382-8. PubMed ID: 19846672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.
    Sooryanarain H; Rogers AJ; Cao D; Haac MER; Karpe YA; Meng XJ
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C.
    Dumoulin FL; Wennrich U; Nischalke HD; Leifeld L; Fischer HP; Sauerbruch T; Spengler U
    J Hum Virol; 2001; 4(4):195-9. PubMed ID: 11694847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus.
    Fernández M; Quiroga JA; Martín J; Herrero M; Pardo M; Horisberger MA; Carreño V
    J Infect Dis; 1999 Aug; 180(2):262-7. PubMed ID: 10395838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
    Di Bisceglie AM; Fan X; Chambers T; Strinko J
    J Med Virol; 2006 Apr; 78(4):446-51. PubMed ID: 16566033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
    Fujita N; Kaito M; Tanaka H; Horiike S; Urawa N; Sugimoto R; Konishi M; Watanabe S; Adachi Y
    J Viral Hepat; 2006 Mar; 13(3):190-8. PubMed ID: 16475995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response.
    Broering R; Zhang X; Kottilil S; Trippler M; Jiang M; Lu M; Gerken G; Schlaak JF
    Gut; 2010 Aug; 59(8):1111-9. PubMed ID: 20639253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
    Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
    Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrahepatic mRNA expression of interferon-inducible antiviral genes in liver diseases: dsRNA-dependent protein kinase overexpression and RNase L inhibitor suppression in chronic hepatitis C.
    Yu SH; Nagayama K; Enomoto N; Izumi N; Marumo F; Sato C
    Hepatology; 2000 Nov; 32(5):1089-95. PubMed ID: 11050060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C.
    Murata K; Yamamoto N; Kawakita T; Saito Y; Yamanaka Y; Sugimoto K; Shiraki K; Nakano T; Tameda Y
    Hepatogastroenterology; 2005; 52(62):547-51. PubMed ID: 15816475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
    Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes.
    Meier V; Mihm S; Ramadori G
    J Med Virol; 2008 Nov; 80(11):1912-8. PubMed ID: 18814253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
    Taylor MW; Tsukahara T; Brodsky L; Schaley J; Sanda C; Stephens MJ; McClintick JN; Edenberg HJ; Li L; Tavis JE; Howell C; Belle SH
    J Virol; 2007 Apr; 81(7):3391-401. PubMed ID: 17267482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral responses of human Fallopian tube epithelial cells to toll-like receptor 3 agonist poly(I:C).
    Ghosh M; Schaefer TM; Fahey JV; Wright JA; Wira CR
    Fertil Steril; 2008 May; 89(5 Suppl):1497-506. PubMed ID: 17669408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.
    Zekri AR; Haleem HA; Esmat GE; Bahnassy AA; El-Din HM; Hafez MM; Sharaby AF; Sharaf H; Zakaria MS
    J Viral Hepat; 2007 Jul; 14(7):468-77. PubMed ID: 17576388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
    Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
    Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.